Pharmacy Service, Instituto de Investigación Biomédica de A Coruña (INIBIC), Complexo Hospitalario Universitario de A Coruña (CHUAC). Sergas. Universidade da Coruña (UDC), A Coruña, Spain
Pharmacy Service, Instituto de Investigación Biomédica de A Coruña (INIBIC), Complexo Hospitalario Universitario de A Coruña (CHUAC). Sergas. Universidade da Coruña (UDC), A Coruña, Spain.
Eur J Hosp Pharm. 2020 Nov;27(6):346-349. doi: 10.1136/ejhpharm-2018-001840. Epub 2019 Mar 18.
Fingolimod is the first oral drug indicated in monotherapy as a modifier of the course of very active relapsing-remitting multiple sclerosis (RRMS). The safety profile of fingolimod is well established in clinical trials and post-marketing studies. Our objective was to study the profile of fingolimod use in our health area.
A retrospective, observational, descriptive study was performed on the use of fingolimod in adult patients diagnosed with RRMS between January 2015 and February 2017 or until suspension of treatment in a reference hospital in north-western Spain.
A total of 55 patients were included with a mean±SD time of treatment with fingolimod of 26±14.6 months (range 2-53). Thirteen patients permanently discontinued the treatment (10 due to outbreaks/disease progression and 3 due to adverse effects). No statistically significant differences were found between the percentage of patients who discontinued fingolimod and who had received only one previous treatment and those who had received two or more treatments. No cases of symptomatic bradycardia were reported.
Fingolimod is a safe treatment for patients with multiple sclerosis.
芬戈莫德是首个被批准用于治疗极活跃复发缓解型多发性硬化症（RRMS）的单药疗法的口服药物。芬戈莫德在临床试验和上市后研究中的安全性已得到充分证实。我们的目的是研究芬戈莫德在我们的医疗区域的使用情况。
对 2015 年 1 月至 2017 年 2 月期间在西班牙西北部一家参考医院被诊断为 RRMS 的成年患者使用芬戈莫德的情况进行了回顾性、观察性、描述性研究，或直至停止治疗。
共纳入 55 例患者，平均±SD 芬戈莫德治疗时间为 26±14.6 个月（范围 2-53）。13 例患者永久性停药（10 例因爆发/疾病进展，3 例因不良反应）。接受过一次以上治疗的患者与仅接受过一次治疗的患者相比，停药的比例无统计学差异。未报告有症状性心动过缓的病例。
芬戈莫德是一种治疗多发性硬化症患者的安全治疗方法。
